Why PBM Comparisons Matter More Now
A PBM comparison does more than rank discounts and rebates. It helps a client decide how to manage pharmacy cost, what changes members may experience and what to expect from the contract.
When the assumptions behind that comparison are unclear, the recommendation becomes harder to explain. When they are clear, the broker can show what is driving the expected result and where the trade-offs sit.
That distinction matters for three reasons: the dollars involved, the visibility expected and the responsibility to keep reviewing the decision after placement.
More spend is riding on the decision
Business Group on Health’s 2027 employer survey identifies pharmacy as a significant source of cost pressure, with GLP-1 use, complex therapies and chronic conditions among the contributors.
For a broker, the implication is to understand how the management strategy behind the quote affects the client’s expected spend. What it’s not is simply to negotiate a stronger discount.
A different preferred therapy, a change in program participation or a shift in where a drug is administered can change the projection. A headline guarantee may not make those differences visible.
This is where the first article’s distinction matters: better unit pricing and lower total spend are not automatically the same result. The comparison needs to show the effect of pricing alongside the effect of drug mix and utilization.
The larger the financial decision, the more important it is to know what is driving it.
More transparency is expected
Transparency begins with knowing what is being paid and to whom. For covered brokerage and consulting arrangements with ERISA group health plans, federal disclosure requirements already address expected direct and indirect compensation. The Department of Labor explains that the information generally must be provided reasonably in advance of entering into the arrangement.
Compensation disclosure is one part of the picture. It does not, by itself, establish that two PBM proposals are comparable or that one will produce a better economic result.
The analysis still needs to make its definitions, assumptions and exclusions visible. Which drugs fall under each guarantee? What utilization was assumed? Which program effects are included in the savings projection?
Getting to the number matters. Being able to explain it does too.
Fiduciary oversight continues after selection
Department of Labor guidance describes hiring a service provider as a fiduciary function and emphasizes documenting selection and monitoring processes. It also calls for periodic review of service-provider performance and fees.
For the broker supporting that work, a clear recommendation should leave a usable record of the analysis: the information considered, the assumptions applied, the trade-offs evaluated and the reasons for the recommendation.
That record also provides a starting point for reviewing performance. If results differ from the projection, the team needs to distinguish changes in utilization or drug mix from a missed contractual commitment.
A reprice is a projection. The contract determines what the PBM is accountable for.
Documenting the process does not guarantee a financial result or eliminate legal risk. It makes the reasoning available for review and helps identify what needs attention next.
The pressures converge on the same decision
Spend, transparency and oversight are not three separate reasons to build three different processes. They all point to the value of one clear evaluation.
The comparison should show why one strategy is expected to produce a better result, what changes that strategy asks members to make and which commitments can be tested after implementation.
That is more useful than treating defensibility as a separate exercise at the end. The same analysis that supports the recommendation should help the client understand the economics and give the team a basis for ongoing review.
In the final article, we turn that principle into three practical checks: establish an independent baseline, translate the definitions and normalize utilization before comparing price.
For the full campaign framework, read How Brokers Make PBM Recommendations That Hold Up.